• Home
  • Blog
  • Newsroom
  • Publications
  • Jobs
  • Get involved
  • Contact us
Search main website

PATHPATH

Driving transformative innovation to save lives

  • Who we are
  • What we do
  • Where we work
  • Resources
About giving »
Donate now »

Publications : Browse

Browse PATH publications

Filter browse results

Total results with these characteristics: 9

Subject: Drug Development
Publication date: All

Page 1 of 1
Advancing iOWH032: Novel Antisecretory Drug for the Treatment of Cholera

PATH and partners are developing iOWH032 as a complement to oral rehydration solution for diarrheal disease treatment. Acting via inhibition of the cystic fibrosis transmembrane conductance regulator chloride channel, iOWH032 is a novel, low-molecular-weight compound intended to reduce fluid and electrolyte loss in cases of cholera toxin-induced secretory diarrhea.

Publication date: August 2017

Region: Global

Improving Treatment For Parasitic Worms

As part of the Tribendimidine (TrBD) Consortium, PATH and partners are advancing TrBD—an anthelmintic drug with demonstrated excellent efficacy against soil-transmitted helminth (STH) infections—as an additional drug option for control and treatment of STH. Integration of TrBD into global mass drug administration campaigns could accelerate progress to eliminate STH in endemic regions.

Publication date: August 2017

Region: Global

PATH's Drug Development Program

The Drug Development program represents a key innovation platform at PATH. Guided by a passion for health equity, we work with public- and private-sector stakeholders to develop and advance medicines for diseases disproportionately affecting women and children in low-resource settings. Areas of focus include enteric and diarrheal diseases, neglected tropical diseases, and maternal and child health.

Publication date: August 2017

Region: Global

Pediatric Cryptosporidiosis: An Evaluation of Health Care and Societal Costs in Peru, Bangladesh and Kenya (PLoS One.12(8): e0182820) (journal article)

Cryptosporidium is a leading cause of pediatric diarrhea in resource-limited settings; yet, few studies report the health care costs or societal impacts of this protozoan parasite. This study examined direct and indirect costs associated with symptomatic cryptosporidiosis in infants younger than 12 months in Kenya, Peru and Bangladesh.

Author: Rafferty E, Schurer J, Arndt M, Choy R, de Hostos E, Shoultz D, Farag M

Publication date: 2017

Region: Global

Host-Targeted Therapies for Acute Secretory Diarrhea: A Survey of Clinical-Stage Drug Candidates Across Multiple Pathogenic Mechanisms

Host antisecretory targets are a promising treatment option for easing the symptoms of diarrheal disease and addressing shortcomings of existing therapies. This poster presentation from the American Society of Tropical Medicine and Hygiene 2016 Annual Meeting summarizes the results of tests comparing several clinical-stage drug candidates that have the potential to treat acute secretory diarrhea.

Publication date: November 2016

Region: Global

Part of series: ASTMH posters

Focused Pharmacovigilance for Kala-azar in Nepal

PATH, in collaboration with the Epidemiology & Disease Control Division, Government of Nepal, and B.P. Koirala Institute of Health Sciences, Dharan, is implementing a focused pharmacovigilance program for kala-azar, or visceral leishmaniasis (VL), in Nepal. The program aims to strengthen patient safety and care associated with the use of VL drugs. The results of the pharmacovigilance activities are summarized in this newsletter.

Publication date: May 2016

Region: Asia

Part of series: Pharmacovigilance newsletters

Focused Pharmacovigilance for Kala-azar in Bangladesh

PATH, in collaboration with the Directorate General Health Services (DGHS), Directorate General Drug Administration (DGDA), Government of Bangladesh (GoB) and International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), is implementing a focused pharmacovigilance program for kala-azar, or visceral leishmaniasis (VL), in Bangladesh. The program aims to strengthen patient safety and care associated with the use of VL drugs. The results of the pharmacovigilance activities are summarized in this newsletter.

Publication date: April 2016

Region: Asia

Part of series: Pharmacovigilance newsletters

Pharmacokinetics and Tolerability of iOWH032, an Inhibitor of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Channel, in Normal Volunteers and Cholera Patients

This poster presentation from Digestive Disease Week 2014 summarizes the results of a study comparing the pharmacokinetic profiles of a single dose of 300 mg iOWH032 in healthy American volunteers, healthy Bangladeshi volunteers, and Bangladeshi cholera patients with severe diarrhea. In addition, the safety of iOWH032 was assessed in these different populations.

Publication date: April 2014

Region: Global

Developing Novel Antisecretory Drugs to Treat Infectious Diarrhea

The cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel offers an attractive target for developing a novel antisecretory to treat infectious diarrhea because it is the primary driver of secretion in cases of diarrhea caused by cholera. iOWH032 is a synthetic CFTR inhibitor that has been studied for this indication.

Author: de Hostos EL, Choy RKM, Nguyen T

Publication date: 2011

Region: Global

Page 1 of 1

Browse publications

  • All publications
  • About PATH's work
  • Emerging and epidemic diseases
  • For advocates and policymakers
  • Health technologies
  • Maternal and child health
  • Reproductive health
  • Vaccines and immunization

Search publications

Publications by type

  • Publications by series
  • Publications by language

Publications info

  • Publications FAQ

Share this page

Get updates

Enter your email address for news and updates from PATH. Also, see the topic-specific newsletters we offer.

Connect

  • Get involved
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Pinterest
  • Google+
  • Instagram
  • Contact

About

  • Our story
  • Leadership
  • Finances
  • Where we work
  • Frequently asked questions
  • Press releases

Explore

  • PATH Blog
  • Multimedia
  • Stories
  • Publications
  • Programs and projects
  • The Vaccine Resource Library
  • Jobs

Donate

  • Donate now
  • Why give?
  • Planned giving
  • Good stewardship
Charity Navigator logo with additional label, ‘13 years at four stars!’
  • Home
  • Current RFPs
  • Privacy policy
  • Copyright policy
  • Terms of use

© 1995–2018, PATH

PATH

PATH Home

About PATH

  • About us
  • Four decades of innovation
  • The birth of PATH
  • Finances
  • FAQs

Leadership

  • Executive leaders
  • Board of directors
  • Program leaders
  • Shared services leaders

How we work

  • Corporate partnerships
  • Leadership councils
  • Global Health Innovation Hub
  • Accountability

Impact

  • Annual reports
  • Stories from the field
  • Awards and honors

Featured

Stylized treatment of the number 40.

Celebrating 40 years of innovation to save lives

Close menu

Our areas of expertise

  • Advocacy and policy
  • Applied behavioral communication
  • Devices
  • Diagnostics
  • Digital health solutions
  • Diarrheal disease and pneumonia
  • Drugs
  • Epidemic and emerging diseases
  • HIV/AIDS
  • Malaria
  • Market dynamics
  • Monitoring and evaluation
  • Neglected tropical diseases
  • Noncommunicable diseases
  • Nutrition
  • Reproductive health
  • Safe birth and newborn care
  • System and service innovations
  • Tuberculosis
  • Vaccines
  • Water, air, sanitation, and hygiene
  • Women's cancers

Featured

Man holding Sayana Press.

Sayana Press injectable contraceptive

Close menu

Global reach

  • Our global expertise
  • Belgium
  • China
  • Democratic Republic of the Congo
  • Ethiopia
  • Ghana
  • India
  • Kenya
  • Malawi
  • Mozambique
  • Myanmar
  • Peru
  • Senegal
  • South Africa
  • Switzerland
  • Tanzania
  • Uganda
  • Ukraine
  • Vietnam
  • Zambia

Featured

Illustration of a globe.

Explore our expertise around the world

Close menu

For our colleagues

  • PATH programs
  • Publications
  • Vaccine Resource Library
  • Online resources

Other resources

  • Jobs
  • Get involved
  • Newsroom
  • Contact us

Featured

Gloved hands hold a prototype of the new SD BIOLINE Onchocerciasis IgG4 rapid test.

One-stop-shop for vaccine and immunization resources

Close menu

PATH Blog

Newsroom

Jobs

About giving

Contact us